Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER)

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorapaxar (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms TRA-CER
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough

Most Recent Events

  • 02 Sep 2024 Results (TRACER substudy) assessing assess the prognostic value of NT-proBNP over time in patients with ACS both in the acute setting and when re-assessed after one month presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
  • 07 Nov 2022 Results assessing short- and long-term effects of vorapaxar (V) as compared to Placebo (PL) on the following biomarkers: Angiopoietin-2 (ANGPT2), Angiopoietin-like 4 (ANGPTL4), VEGF, ICAM-1, VCAM-1, E-Selectin (ESEL), von Willebrand Factor (VWF), Thrombomodulin (TM), PAI-1 and PAI-2 from TRA2P-TIMI 50 and TRACER presented at the American Heart Association Scientific Sessions 2022
  • 01 Nov 2022 Results assessing Biomarker-Based Prediction( from two trials NCT00391872 and NCT00527943) of Recurrent Ischemic Events in Patients With Acute Coronary Syndromespublished in the Journal of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top